Emma Link

Peter MacCallum Cancer Institute
Country flagAustralia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Purpose: Long-course chemoradiotherapy (LCCRT) for locally advanced rectal cancer (LARC) achieves a pathologic complete response (pCR) in approximately 10% to 30% of cases. Radiotherapy exerts both immunostimulatory and immunosuppressive effects. Inhibition of PDL1 may augment the immunostimulatory response. We hypothesize that administering avelumab following LCCRT may enhance tumor response and reduce relapse rates. Patients and Methods: This was a phase II single-arm trial. Eligible patients had MRI stage T3b to 4/N1 to 2/M0 LARC within 12 cm from the anal verge. Treatment consisted of long-course chemoradiotherapy (LCCRT) with 50.4 Gy and 5-fluorouracil or capecitabine, followed by four cycles of avelumab (10 mg/kg every 2 weeks). Surgical resection was performed 10 to 12 weeks after completion of LCCRT. Fresh tumor biopsies/ctDNA were taken before LCCRT, before avelumab, and at surgery. The primary endpoint was pCR, reported centrally. Secondary endpoints were imaging responses and toxicity, and exploratory endpoints were translational studies (immune evaluation by multiplex IHC and biopsy-derived tumoroids), distant relapse-free survival, and relapse sites. Results: Thirty-seven patients entered the trial, of whom 33 received avelumab and 32 had surgery. The overall response rate by pelvic MRI (N = 33) was 48%. By 2-[¹⁸F]fluoro-2-deoxy-D-glucose PET, there were 10 complete metabolic responses (CMR) and 18 partial metabolic responses (PMR). Regression score 0 (modified Ryan pCR) was observed in 19% of patients (N = 6), and regression score 1 in 16% (N = 5). Overall, 34% of patients (N = 11) had a major pathologic response. Tumors with greater PDL1 expression showed superior pCR/tumor regression. Tumoroid studies indicated intact cellular machinery for PDL1/HLA class-1 expression modulated by IFNγ. No immune-related grade 3 adverse events were observed, and postoperative complications were as expected. The median follow-up was 3.1 years, the 3-year estimated time to progression was 82%, distant relapse-free survival was 80%, and disease-free survival was 80%. Conclusions: The Ave-Rec phase II study demonstrated that avelumab after LCCRT is deliverable and tolerable, with significant imaging responses and a major pathologic response rate. Tumoral immune cell subsets/checkpoint expression was predictive of pathologic response. The addition of immune checkpoint inhibitors warrants further evaluation in patients with LARC.

Year:

2025

Year:

2025

Purpose: Long-course chemoradiotherapy (LCCRT) for locally advanced rectal cancer (LARC) achieves a pathologic complete response (pCR) in approximately 10% to 30% of cases. Radiotherapy exerts both immunostimulatory and immunosuppressive effects. Inhibition of PDL1 may augment the immunostimulatory response. We hypothesize that administering avelumab following LCCRT may enhance tumor response and reduce relapse rates. Patients and Methods: This was a phase II single-arm trial. Eligible patients had MRI stage T3b to 4/N1 to 2/M0 LARC within 12 cm from the anal verge. Treatment consisted of long-course chemoradiotherapy (LCCRT) with 50.4 Gy and 5-fluorouracil or capecitabine, followed by four cycles of avelumab (10 mg/kg every 2 weeks). Surgical resection was performed 10 to 12 weeks after completion of LCCRT. Fresh tumor biopsies/ctDNA were taken before LCCRT, before avelumab, and at surgery. The primary endpoint was pCR, reported centrally. Secondary endpoints were imaging responses and toxicity, and exploratory endpoints were translational studies (immune evaluation by multiplex IHC and biopsy-derived tumoroids), distant relapse-free survival, and relapse sites. Results: Thirty-seven patients entered the trial, of whom 33 received avelumab and 32 had surgery. The overall response rate by pelvic MRI ( N = 33) was 48%. By 2-[¹⁸F]fluoro-2-deoxy-D-glucose PET, there were 10 complete metabolic responses (CMR) and 18 partial metabolic responses (PMR). Regression score 0 (modified Ryan pCR) was observed in 19% of patients ( N = 6), and regression score 1 in 16% ( N = 5). Overall, 34% of patients ( N = 11) had a major pathologic response. Tumors with greater PDL1 expression showed superior pCR/tumor regression. Tumoroid studies indicated intact cellular machinery for PDL1/HLA class-1 expression modulated by IFNγ. No immune-related grade 3 adverse events were observed, and postoperative complications were as expected. The median follow-up was 3.1 years, the 3-year estimated time to progression was 82%, distant relapse-free survival was 80%, and disease-free survival was 80%. Conclusions: The Ave-Rec phase II study demonstrated that avelumab after LCCRT is deliverable and tolerable, with significant imaging responses and a major pathologic response rate. Tumoral immune cell subsets/checkpoint expression was predictive of pathologic response. The addition of immune checkpoint inhibitors warrants further evaluation in patients with LARC.

Year:

2025

Purpose: BRAF V600E mutant metastatic colorectal cancer represents a significant clinical problem, with combination approaches being developed clinically with oral BRAF inhibitors combined with EGFR-targeting antibodies. While compelling preclinical data have highlighted the effectiveness of combination therapy with vemurafenib and small-molecule EGFR inhibitors, gefitinib or erlotinib, in colorectal cancer, this therapeutic strategy has not been investigated in clinical studies. Patients and Methods: We conducted a phase Ib/II dose-escalation/expansion trial investigating the safety/efficacy of the BRAF inhibitor vemurafenib and EGFR inhibitor erlotinib. Results: Thirty-two patients with BRAF V600E positive metastatic colorectal cancer (mCRC) and 7 patients with other cancers were enrolled. No dose-limiting toxicities were observed in escalation, with vemurafenib 960 mg twice daily with erlotinib 150 mg daily selected as the recommended phase II dose. Among 31 evaluable patients with mCRC and 7 with other cancers, overall response rates were 32% [10/31, 16% (5/31) confirmed] and 43% (3/7), respectively, with clinical benefit rates of 65% and 100%. Early ctDNA dynamics were predictive of treatment efficacy, and serial ctDNA monitoring revealed distinct patterns of convergent genomic evolution associated with acquired treatment resistance, with frequent emergence of MAPK pathway alterations, including polyclonal KRAS , NRAS , and MAP2K1 mutations, and MET amplification. Conclusions: The Erlotinib and Vemurafenib In Combination Trial study demonstrated a safe and novel combination of two oral inhibitors targeting BRAF and EGFR. The dynamic assessment of serial ctDNA was a useful measure of underlying genomic changes in response to this combination and in understanding potential mechanisms of resistance.

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Collaborators (11)

Sarah-Jane Dawson

Medical Oncologist and Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Chan Yoon Cheah

University of Western Australia

AUSTRALIA
View details

David Ritchie

Head of BMT

-

AUSTRALIA
View details

Eva Segelov

MONASH UNIVERSITY

AUSTRALIA
View details

Robert Ramsay

Professor, Laboratory Head /Senior Principal Research Fellow

Peter MacCallum Cancer Centre

AUSTRALIA
View details

Ben Tran

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Grant McArthur

Lorenzo Galli Chair of Melanoma and Skin Cancers

University of Melbourne

AUSTRALIA
View details

Jayesh Desai

Associate Director, Clinical Research / Medical Oncology Lead and Trials Lead

-

AUSTRALIA
View details

Benjamin Solomon

Professor

University of Melbourne

AUSTRALIA
View details

Nick Pavlakis

Professor

University of Sydney

AUSTRALIA
View details

Rachel Wong

Walter and Eliza Hall Institute of Medical Research

AUSTRALIA
View details